PHASE III RANDOMIZED TRIAL OF STANDARD SYSTEMIC THERAPY (SST) VERSUS STANDARD SYSTEMIC THERAPY PLUS DEFINITIVE TREATMENT (SURGERY OR RADIATION) OF THE PRIMARY TUMOR IN METASTATIC PROSTATE CANCER Save

Date Added
March 19th, 2019
PRO Number
Pro00086529
Researcher
David Marshall

List of Studies


Profiles_link
Keywords
Cancer, Cancer/Genitourinary, Prostate
Summary

This study is for men who have prostate cancer. The purpose of this study is to compare the effects, good and/or bad, of adding either prostate removal surgery or radiation therapy of the prostate to standard systemic therapy (SST), which is used to treat prostate cancer.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) Save

Date Added
March 12th, 2019
PRO Number
Pro00086655
Researcher
Irl Greenwell

List of Studies

Silhouette
Keywords
Cancer, Cancer/Leukemia
Summary

This study is for patients that have been diagnosed with chronic lymphocytic leukemia (CLL). The investigational drugs in this study are ibrutinib, obinutuzumab and venetoclax. The purpose of this study is to compare the usual treatment of ibrutinib and obinutuzumab to a combination treatment of ibrutinib and obinutuzumab plus the study drug, venetoclax.

Institution
MUSC
Recruitment Contact
Nancy McGaha
864-725-7129
nmcgaha@selfregional.org

The Impact of a Gravity versus Vacuum Based Indwelling Tunneled Pleural Drainage System on Pain: A Multicenter, Randomized Trial Save

Date Added
March 7th, 2019
PRO Number
Pro00084785
Researcher
Nicholas Pastis

List of Studies


Profiles_link
Keywords
Cancer
Summary

The purpose of this study is to compare the effects (good and bad) of the different types of drainage in people receiving indwelling tunneled pleural catheters and the effect this has on pain during the drainage period.

Institution
MUSC
Recruitment Contact
Katherine Wallace
843-792-4557
wallacka@musc.edu

A Phase II Trial Assessing the Tolerability of Palbociclib in Combination With Letrozole or Fulvestrant in Patients Aged 70 and Older With Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer Save

Date Added
March 4th, 2019
PRO Number
Pro00086652
Researcher
Frank Brescia

List of Studies


Profiles_link
Keywords
Cancer, Cancer/Breast
Summary

This study is for patients who are 70 years old or over and have been recently diagnosed with estrogen receptor positive, HER2 negative metastatic breast cancer. The purpose of this study is to find out the side effects that the standard, FDA-approved combination treatment of letrozole or fulvestrant and palbociclib has on patients 70 years old and over.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

OLANZAPINEWITH ORWITHOUT FOSAPREPITANT FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC): A PHASE III RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED TRIAL Save

Date Added
March 1st, 2019
PRO Number
Pro00086739
Researcher
Scott Lindhorst

List of Studies


Profiles_link
Keywords
Cancer
Summary

This study is for patients receiving treatment for cancer that may cause side effects of nausea and vomiting. The purpose of this study is to see if olanzapine given in combination with other standard drugs, is still as effective without using the fosaprepitant.

Institution
MUSC
Recruitment Contact
Nancy McGaha
864-725-5105
nmcgaha@selfregional.org

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma Save

Date Added
February 26th, 2019
PRO Number
Pro00086647
Researcher
Daniel Reuben

List of Studies

Silhouette
Keywords
Cancer, Cancer/Skin
Summary

This study is for patients that have been diagnosed with Merkle Cell Carcinoma. The investigational drug in this study is pembrolizumab. The purpose of this study is to compare the usual approach of post-surgery observation with or without radiation to using pembrolizumab with or without radiation after surgery. Participants can expect to be on this study for a total of 5 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy Save

Date Added
February 19th, 2019
PRO Number
Pro00086308
Researcher
Scott Lindhorst

List of Studies


Profiles_link
Keywords
Cancer, Cancer/Brain, Glioblastoma
Summary

This study is for men and women with glioblastoma. The purpose is to see if we can lower the chance of memory loss by adding the drug Ramipirl to the usual chemoradiation treatment.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase 2b, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults with Newly-Diagnosed Acute Myeloid Leukemia, Not Eligible for Standard Induction Therapy Save

Date Added
January 8th, 2019
PRO Number
Pro00083544
Researcher
Robert Stuart

List of Studies


Profiles_link
Keywords
Cancer, Drug Studies, Men's Health, Women's Health
Summary

This study is for subjects with newly-diagnosed acute myeloid leukemia (AML) who are not eligible for standard induction chemotherapy. The investigational drug in this study is BST-236, which is given via IV. The purpose of this research study is to measure the safety of BST-236 and how effective it is in treating subjects. Visits will be required for 6 consecutive days during each cycle of treatment. The number of courses you receive will depend on whether you are benefiting from the study drug. Participants can expect to be in this study for 2 years (including treatment and post study follow-up).

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients Save

Date Added
January 7th, 2019
PRO Number
Pro00083234
Researcher
Jacqueline Kraveka

List of Studies


Profiles_link
Keywords
Adolescents, Cancer, Pediatrics
Summary

This study is for patients that have been diagnosed with a pediatric brain tumor called medulloblastoma. The purpose of this study is to find out if a reduced dose of radiation to the whole brain and spine and less chemotherapy can be given to children and young adults with WNT subtype medulloblastoma without increasing the risk of the tumor coming back. Participants can expect to be in this study for about one year, and then followed for up to 10 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Evaluation of the CytoRADxTM System as a Biodosimeter with Human Subjects Receiving Radiation Therapy Save

Date Added
December 18th, 2018
PRO Number
Pro00081783
Researcher
Gary Headden

List of Studies


Profiles_link
Keywords
Cancer
Summary

The study is designed to evaluate the response of potential biomarkers generated by the CytoRADx assay on blood samples from human subjects receiving two general forms of radiation treatment: a) total body irradiation and b) localized fractionated radiation treatment for selected anatomic sites.

Blood samples will be obtained from patients undergoing radiation treatment as part of their standard of care treatment for their underlying disorder/disease which will usually be cancer. The samples will be obtained both prior to and following their radiation treatment.

The samples will then be shipped for comparison of CytoRADx results on various lymphocyte subsets in those patients' blood samples.

Institution
MUSC
Recruitment Contact
Robert Houck
843-792-3576
houckr@musc.edu

Change_preferences

-- OR --

Create_login